Weighing the Benefits and Risks of an Oral Carbapenem Option

This episode, "Weighing the Benefits and Risks of an Oral Carbapenem Option," has the panel weighing exactly who should, and shouldn't, receive the field's newest oral option.

Dr. Gupta asks Dr. Kaye to weigh the strengths and risks of having an oral carbapenem option available. Dr. Kaye calls avoiding hospitalization entirely the biggest opportunity. Patients who are not sick enough to require admission on hemodynamic grounds previously had no systemically absorbed oral option and were admitted for intravenous therapy alone. That exposed them to fall risk, hospital-acquired infection, and extended stays that often stretched beyond a day or two. He describes a recent patient with an obstructing kidney stone and an extended-spectrum beta-lactamase infection who lacked a safe oral option to bridge care until urology could intervene. He calls the new oral carbapenem potentially life-saving in that scenario. On risk, Dr. Kaye flags four-times-daily dosing as a practical adherence challenge, especially as patients start feeling better and returning to normal routines. He also raises the broader concern of accelerating carbapenem resistance if the drug is used for asymptomatic bacteriuria rather than genuine infection. Dr. Gupta then asks Dr. Nelson how stewardship programs should select appropriate patients. Dr. Nelson explains that stewardship traditionally concentrates inside hospital walls, making outpatient oversight far harder. This matters particularly as extended-spectrum beta-lactamase infections increasingly reach primary care, urgent care, and emergency department settings without infectious diseases involvement. His team has discussed electronic health record prompts and appropriate-use criteria to flag off-label use, despite clinicians' well-known aversion to additional pop-ups. Dr. Kaye and Dr. Pogue add that large, consolidated health systems are increasingly building system-wide pharmacy and therapeutics committees and stewardship structures. Dr. Nelson cautions, though, that specialized expertise still concentrates in urban centers, leaving smaller, critical-access sites needing dedicated education and support to use the new agent appropriately.

Our next episode, "Expanding Oral Carbapenem Use: Guardrails and Real-World Evidence Needs," looks at where oral carbapenem use is already headed beyond its approved indication.